UNSPSC 51203404: Mercaptopurine anhydrous

This classification denotes a purine antagonist and immunosuppressant C5H4N4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PKK6MUZ20G, chemically known as 1,9-dihydro-6h-purine-6-thione, but more generally known as mercaptopurine anhydrous, which bears US NIH Compound Identifier 667490. Most nations, for tariff and trade purposes, schedule mercaptopurine anhydrous under HS 29335995 and SITC 51576. As of Q4 2014, MERCAPTOPURINE ANHYDROUS remains US FDA's Preferred Term for this commodity.

Mercaptopurine anhydrous bears US NLM identifiers UMLS ID C1881785 and NCI Concept Code C61832. SMILES: C1[NH]C2C(N1)C(=S)[NH]CN2.

UNSPSC 51203404 Mercaptopurine anhydrous is a Commodity code that shows significant mismatch between its nominal scope and recent state and local procurement activity. The recent opportunities tagged under this code do not solicit mercaptopurine or related pharmaceutical active ingredients; instead, they reflect demand for finished medical and pharmaceutical products—naloxone units, safe drug deactivation systems, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products distributed through wholesaler networks. State and local buyers posting under this code include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire and rescue services (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across participating jurisdictions including Oregon). The code shows little relevant recent activity for the active pharmaceutical ingredient it nominally describes.

Geographic spread spans Florida (Seminole County), Texas (HHS Commission), Minnesota and Oregon (MMCAP), with single recent opportunities in each jurisdiction. Representative recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, with quarterly deliveries to the county community health building); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000.00 and designated for certified Small Local Business Enterprises with a 5 percent bid discount, due March 13, 2026; and Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers, due March 26, 2026, with contract effectiveness July 1, 2026. The mismatch between the code's pharmaceutical-ingredient focus and the actual procurement of finished medical products and distribution services suggests this code may not be the appropriate taxonomy path for vendors pursuing state and local opportunities in emergency medical supplies and pharmacy benefit management.